M. Botta
University of Turin
9 Papers
96 Citations
M. Botta is an academic researcher from University of Turin. The author has contributed to research in topics: Pemetrexed & Mesothelioma. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
Phase II Study of Vinorelbine With Protracted Fluorouracil Infusion as a Second- or Third-Line Approach for Advanced Breast Cancer Patients Previously Treated With Anthracyclines
Alfredo Berruti,Paola Sperone,Alberto Bottini,Gabriella Gorzegno,Vito Lorusso,A. Brunelli,M. Botta,Marco Tampellini,Michela Donadio,S. Mancarella,Mario De Lena,P Alquati,Luigi Dogliotti +12 more
TL;DR: Vinorelbine associated with protracted infusional fluorouracil is an active and manageable scheme in advanced breast cancer patients previously treated with anthracycline-containing regimens and the response obtained is durable.
49
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
Giovanni Luca Ceresoli,Federica Grosso,Paolo Andrea Zucali,Manlio Mencoboni,Giulia Pasello,C. Ripa,D. Degiovanni,Matteo Simonelli,Andrea Bruzzone,C Dipietrantonj,E. Piccolini,Giordano D. Beretta,Adolfo Favaretto,Laura Giordano,Armando Santoro,M. Botta +15 more
TL;DR: Non-epithelioid histology, age ⩾75 years, advanced IMIG stage and presence of comorbidities according to CCI were significant prognostic factors in elderly patients with MPM.
Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control.
Nicla La Verde,Anna Moretti,Gabriella Farina,Maria Chiara Dazzani,Teresa Gamucci,Karen Borgonovo,M. Botta,Nello Salesi,Monica Zuradelli,Ida Pavese,Elena Barbieri,Elisabetta Cretella,Tiziana Saladino,Paola Varese,Elena Silvia Traverso,Gianfranco Addamo,Mariangela Ciccarese,Anna Iolanda Rispoli,Arianna Pellegrino,Lucia Mentuccia,Serena Girelli,Sheila Piva,Massimo Di Maio +22 more
TL;DR: The response rate of skin metastasis to eribulin treatment was coherent with systemic responses and the good clinical response in most patients reflected symptom improvement.
7
Pemetrexed (MTA) and carboplatin (CBDCA) in the treatment of advanced pleural mesothelioma (MPM)
B. Castagneto,Manlio Mencoboni,D. Degiovanni,A. Muzio,L. Giaretto,L. Rebella,Oscar Alabiso,R. Buosi,M. Cafferata,M. Botta +9 more
TL;DR: The results of this phase II study indicate that the combination of CBDCA and MTA is moderately active and that the profile of toxicity is acceptable in pts with advanced MPM.
5
Aurora B kinase and malignant mesothelioma.
Pier Giacomo Betta,T. Bensi,N. F. Trincheri,E. Arnolfo,Roberta Libener,M. Botta,E. Piccolini,G. Bottero,Federica Grosso,Sara Orecchia +9 more
TL;DR: An aggressive neoplasm of the serosal cavities, resistant to conventional treatment, for which new therapeutic targets are being actively sought is being actively pursued.
2